89bio Inc.

3.44-0.0300-0.86%Vol 262.89K1Y Perf -84.06%
Jun 27th, 2022 16:00 DELAYED
BID3.35 ASK3.80
Open3.42 Previous Close3.47
Pre-Market- After-Market3.45
 - -  0.01 0.29%
Target Price
32.56 
Analyst Rating
Strong Buy 1.11
Potential %
846.51 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.09 
Earnings Rating
Market Cap70.01M 
Earnings Date
11th Aug 2022
Alpha-0.06 Standard Deviation0.25
Beta1.72 

Today's Price Range

3.233.53

52W Range

2.0022.31

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
8.78%
1 Month
32.95%
3 Months
-16.18%
6 Months
-73.93%
1 Year
-84.06%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ETNB3.44-0.0300-0.86
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.38-1.268.70
Q04 2021-1.51-1.3013.91
Q03 2021-1.07-1.41-31.78
Q02 2021-0.86-1.03-19.77
Q01 2021-0.67-0.74-10.45
Q04 2020-0.90-0.6330.00
Q03 2020-0.89-0.863.37
Q02 2020-0.85-0.850.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-1.17
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume262.89K
Shares Outstanding20.35K
Shares Float8.18M
Trades Count1.96K
Dollar Volume882.05K
Avg. Volume381.68K
Avg. Weekly Volume490.12K
Avg. Monthly Volume379.00K
Avg. Quarterly Volume275.92K

89bio Inc. (NASDAQ: ETNB) stock closed at 3.47 per share at the end of the most recent trading day (a -4.14% change compared to the prior day closing price) with a volume of 1.12M shares and market capitalization of 70.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. 89bio Inc. CEO is Rohan Palekar.

The one-year performance of 89bio Inc. stock is -84.06%, while year-to-date (YTD) performance is -73.45%. ETNB stock has a five-year performance of %. Its 52-week range is between 2 and 22.31, which gives ETNB stock a 52-week price range ratio of 7.09%

89bio Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.63, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -60.35%, a ROC of -60.81% and a ROE of -68.89%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from 89bio Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.17 for the next earnings report. 89bio Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for 89bio Inc. is Strong Buy (1.11), with a target price of $32.56, which is +846.51% compared to the current price. The earnings rating for 89bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

89bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

89bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.11, ATR14 : 0.33, CCI20 : 54.60, Chaikin Money Flow : 0.18, MACD : 0.11, Money Flow Index : 72.88, ROC : -8.68, RSI : 55.40, STOCH (14,3) : 51.38, STOCH RSI : 0.70, UO : 53.49, Williams %R : -48.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 89bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
7 (77.78 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
2 (22.22 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.11
Strong Buy
1.11
Strong Buy
1.22

89bio Inc.

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

CEO: Rohan Palekar

Telephone: +1 415 500-4614

Address: 142 Sansome Street, San Francisco 94104, CA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

48%52%

Bearish Bullish

53%47%

TipRanks News for ETNB

Sun, 15 May 2022 13:26 GMT 89bio (ETNB) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

Fri, 13 May 2022 04:36 GMT 89bio (ETNB) Receives a Buy from BTIG

- TipRanks. All rights reserved.

Fri, 13 May 2022 04:08 GMT 89bio (ETNB) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Thu, 12 May 2022 15:05 GMT Analysts Are Bullish on Top Healthcare Stocks: 89bio (ETNB), Shattuck Labs (STTK)

- TipRanks. All rights reserved.

Fri, 06 May 2022 04:45 GMT Analysts Offer Insights on Healthcare Companies: 1Life Healthcare (ONEM), 89bio (ETNB) and Personalis (PSNL)

- TipRanks. All rights reserved.

News

Stocktwits